1125 N. Charles St, Baltimore, MD 21201. The Motley Fool has a disclosure policy. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Ocugen. Why Ocugen Stock Is Crushing It Today | Nasdaq Like other life sciences companies involved in Covid-19 vaccine. Ocugen isnt a promotional, fly-by-night penny stock. 7 Travel Stocks to Buy Banking On Pent-Up Demand. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. Its all about choice. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. If You Invested $1,000 In Ocugen Stock One Year Ago, Here's - Insider Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. That's right -- they think these 10 stocks are even better buys. However, even from this limited vantage point, OCGN appears destined to fail. Histogenics itself highlights the risks involved in small-cap biotech. *Average returns of all recommendations since inception. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Accordingly, the analyst rates OCGN a Neutral (i.e. But any success they find will be without me as a shareholder. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. *Stock Advisor returns as of November 20, 2020. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. That's not going to happen now. It means that raising capital will be more difficult going forward. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. That's right -- they think these 10 stocks are even better buys. Type a symbol or company name. Do Not Sell My Personal Information (CA Residents Only). Written by Making the world smarter, happier, and richer. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. Conditions have only become worse since that time. See disclosure here. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Do not expect a recovery in Ocugen stock. But realizing value in practice usually is a difficult endeavor. These options will be cheaper than owning the stock itself. The short answer is: everything. Sign up below to get this incredible offer! The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. But the allure of the space is that when a company wins, its shareholders win big. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. The Motley Fool has a disclosure policy. Unfortunately for longs, OCGN is much closer to the worst of conditions. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. Please check your download folder. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. OCGN Stock Forecast 2022 and 2025: Is Ocugen Set to Explode? Custom BMW. These symbols will be available throughout the site during your session. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. The $25 million private placement executed before the merger brought in much-needed cash. Its certainly possible. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Without NeoCart, that burn likely comes down. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. It's hard to say for sure. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. All rights reserved. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. This can prove to be a costly lesson to learn. The Motley Fool has no position in any of the stocks mentioned. The Ocugen deal is a way to salvage some limited value. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. In this case, shares rallied about four-fold in just a few days. Hold) without suggesting a price target. Can you feel the ground moving beneath your feet? The stock had gained some traction after they announced the. So, what goes wrong? The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. The Motley Fool recommends Moderna Inc. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Ill be sticking to the stocks that are actually working. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. To be sure, current cash isnt enough. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. If Ocugen goes up, you can still profit. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Sign up below to get this incredible offer! All rights reserved. Thats the thing with these low-priced penny stocks. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Invest better with The Motley Fool. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. These symbols will be available throughout the site during your session. However, when that occurred, Ocugen stock lost most of its value. If OCU300 is approved, theres a reasonably large market. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Investors need to understand the risk profile here. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. Learn More. ET on Friday. Guys, theres no revenue here! The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. OCGN does not even appear to have an apparent reason to exist. You never know when they will suddenly go on a squeeze. The biotech stock promptly crashed by more than 30%. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. The stock had gained some traction after they announced the Ocugen merger in April. Don't Get Greedy With Ocugen Stock, Says Analyst The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Do Not Sell My Personal Information (CA Residents Only). What should investors do now? Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. This requires no immediate effort on your part. Ocugen sold $25 million of stock in a private placement before the merger. And its at least possible that OCGN could wind up being a winner. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. That doesnt mean success is guaranteed. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion - Stocktwits After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Even before that point, the most promising candidates generally can find funding. It has real management. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Nasdaq The potential synergies of such a union do not seem clear. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Most biotech companies have intriguing stories on paper; Ocugen is no different. Type a symbol or company name. Copyright The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Other than an emphasis on cell therapies, the companies had almost nothing in common. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. market." Investors should worry about companies with no revenue even under the best of circumstances. Create your Watchlist to save your favorite quotes on Nasdaq.com. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Instead, this appears destined to join the long list of failed biotech startups. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. All rights reserved. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. The Motley Fool->. How can we possibly evaluate a stock on a fundamental basis with that being reality? 1125 N. Charles St, Baltimore, MD 21201. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Written by The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. So far, that merger hasnt worked out for Histogenics former shareholders. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. (See OCGN stock analysis on TipRanks). The average Ocugen stock price for the last 52 weeks is 2.10. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. To make the world smarter, happier, and richer. Ocugen Inc. Announces Closing of $100 Million Registered Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Here are three prudent steps to take. Why Ocugen Stock Dropped Today | The Motley Fool - Nasdaq The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. There's still a chance that the vaccine could receive a green light in Canada. Not an offer or recommendation by Stocktwits. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. If they invent a miracle treatment for a condition, the money will find its way to the stock. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Type a symbol or company name. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. The chances of anything more are small but the rewards could be huge. 2023 InvestorPlace Media, LLC. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Literally, zero. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Theres even room for more lines. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. Our 3 Top Picks. The statistics support having long-term exposure to this asset class. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Gw pharmaceuticals stock dividends will nike stock split soon Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. Lorem ipsum dolor sit amet, consectetur adipiscing elit. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. 1125 N. Charles St, Baltimore, MD 21201. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 The Motley Fool has no position in any of the stocks mentioned. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Type a symbol or company name. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. I will concede this: The one great thing about the stock market is there is a style for everyone. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete.